Rafferty Asset Management LLC Sells 6,156 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Rafferty Asset Management LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,472 shares of the biopharmaceutical company’s stock after selling 6,156 shares during the period. Rafferty Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $26,130,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Dodge & Cox grew its holdings in shares of Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares during the period. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $628,151,000. Acadian Asset Management LLC grew its stake in Regeneron Pharmaceuticals by 234.7% in the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after purchasing an additional 326,583 shares during the period. Loomis Sayles & Co. L P raised its holdings in Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after purchasing an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Regeneron Pharmaceuticals by 26.5% in the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after purchasing an additional 225,078 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, HSBC raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Trading Up 1.4%

NASDAQ:REGN opened at $781.67 on Friday. The stock has a market cap of $82.64 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 2.10 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average price is $771.59 and its 200-day moving average price is $681.65. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the firm posted $12.07 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: U.S. FDA approval (announced Feb. 24) expanding Dupixent’s indication to include allergic fungal rhinosinusitis — adds a new labeled population and supports future revenue growth. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: European Medicines Agency recommended Dupixent for approval to treat chronic spontaneous urticaria (CSU) in children aged 2–11 — if approved, this would be the first targeted EU therapy for that pediatric group, extending Dupixent’s addressable market. Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
• Positive Sentiment: Analyst sentiment improved with Wall Street Zen moving REGN to a Buy rating — upgrades can spur additional investor interest and short-term flows. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Wall Street Zen
• Positive Sentiment: Media/analyst pieces and hedge-fund screens continue to highlight Regeneron as a top gene-therapy/big-pharma pick, reinforcing investor narratives around its pipeline and R&D capabilities. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: Dupixent sales momentum remains a core bull case — recent analysis notes ~22.8% YoY growth for Dupixent in Q4 and continued contribution to Regeneron’s top-line strength. Why Dupixent Keeps Regeneron A Top Big Pharma Pick
• Neutral Sentiment: Coverage notes REGN has lagged the Nasdaq over the past year — a reminder of relative performance risk even amid positive fundamental catalysts. Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Insiders Place Their Bets

In related news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 over the last quarter. Corporate insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.